Bluefin Capital Management’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
Bluefin Capital Management's RNA Position: Q3 2026 in Review
Bluefin Capital Management held its Atrium Therapeutics (RNA) position steady in Q3 2026 at 16,011 shares worth $215K. The position accounts for 0.06% of the portfolio, ranked #86.
Bluefin Capital Management first reported a position in RNA in Q2 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- Bluefin Capital Management held 16,011 shares of Atrium Therapeutics worth $215K as of Q3 2026.
- Bluefin Capital Management left its Atrium Therapeutics share count unchanged in Q3 2026.
- Atrium Therapeutics made up 0.06% of Bluefin Capital Management's portfolio in Q3 2026, its #86 holding.
- Bluefin Capital Management first reported a position in Atrium Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on Bluefin Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.